

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 8D




FIGURE 8E




FIGURE 8F




FIGURE 9A




FIGURE 9B




FIGURE 9C




FIGURE 9D




FIGURE 9E




FIGURE 9F




FIGURE 10




FIGURE 11

**Viral concentration at 24 h
when dosing Cmpd. 2 at various time points
in primary human airway epithelial cells**




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15A





FIGURE 15B













	naive-CMC	Naive-Cmpd. 2	SARS-CMC	SARS-Cmpd. 2
day 7				
day 14				
day 21				

FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20

